Global Point of Care
Home > Products

m-PIMA™ HIV-1/2 Viral Load Test

Point-of-Care HIV Viral Load in Less Than 70 Minutes, Not Months

Designed to provide actionable results while the patient is still present.

WHO recommends a viral load test at 6 months and 12 months, and annually thereafter if the patient is stable on ART1, but few patients receive that level of care.

  • UNAIDS 909090 Goal: 90% of patients on ART virally suppressed by 2020, but only 44% actually are.2
  • Approximately 50% of the viral load testing need in low to middle income countries is unmet.2
  • By 2021 low to middle income countries will need an estimated 30 million viral load tests.3

The m-PIMA™ HIV-1/2 VL test is now commercially available in select countries, and has received CE-IVD marking and WHO prequalification. This product is not available in the United States.

Benefits
  • Extend the reach of viral load testing
  • Empower decentralized decision making for better clinical outcomes
  • Empower patients to know their viral load
  • Educate and engage patients on their treatment
  • ART failure, adherence, and switching decisions can be made the same day
  • Reduced sample transport costs
  • Lost samples, lost results, and patients lost to follow up potentially reduced
m-PIMA HIV-1/2 VL
Helpful Documents
  • Lower limit of quantitation: 800 cp/mL for HIV-1 and HIV-2 RNA (below the WHO cut-off value of <1000 cp/mL)
  • Method: Reverse Transcription and Real Time PCR with multiplexing capabilities
  • Time to results: less than 70 minutes
  • Sample volume: 50 μL
  • Sample type: venous EDTA plasma
  • Storage conditions: 4-30°C
  • Connectivity: enabled
m-PIMA™ HIV 1/2 Viral Load Test
 Code
m-PIMA™ Analyser
 27030R001
m-PIMA™ HIV-1/2 VL Cartridge (IVD-CE) 270150050
m-PIMA™ HIV-1/2 VL Cartridge (IVD)
 27015-W50
USB Printer 27040R007
Printer Paper 26040R009
m-PIMA™ HIV Fingerstick Sample Collection Set  270400201

View References

  1. WHO: What’s new in treatment monitoring: viral load and CD4 testing. July 2017
  2. Ending AIDS: progress towards the 90-90-90 targets 2017
  3. Lauren & Biyi, LMIC Forecast Demand for Diagnostic Tests 2016-2021, Avenir Health

Stay informed

Sign up to receive valuable updates from Abbott.